Keryx Biopharmaceuticals Announces Phase 1 / 2 Clinical Trial Results of KRX-0401 Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 